Document:

exv10w6

 

Exhibit 10.6

AMENDED AND RESTATED ENDOCARE SERVICE AGREEMENT

     This AMENDED AND RESTATED ENDOCARE SERVICE AGREEMENT (“Agreement”) is made and entered into
January 9th, 2006, to be effective February 1, 2006, by and between ENDOCARE, INC., a Delaware
corporation (“Endocare”), and Advanced Medical Partners, Inc. dba CryoSyndicators a Delaware
corporation (“Company”) (each a “Party” and together, the “Parties”).

RECITALS

          A. Endocare has developed CryocareTM Surgical Systems (including the CRYO-20 and CRYO-CS
Systems), which are used in connection with cryotherapy.

          B. Endocare has entered into and intends to enter into contracts or other arrangements with
various hospitals (“Hospital Arrangements”), pursuant to which Endocare agrees to make the
CryocareTM Surgical System and related supplies and services available to such hospitals on an
as-needed basis, either directly or through subcontracts with qualified entities. **

          C. Company has purchased or leased one or more CryocareTM Surgical Systems, ultrasound
equipment and other equipment used in conjunction with cryosurgical procedures (collectively, the
“Equipment”) and has employed or contracted with the necessary technical staff in order to be able
to deliver and operate the CryocareTM Surgical Systems in connection with the Hospital Arrangements.

          D. Company also has entered into subcontracts with other organizations (“Business Entities”)
to provide the Equipment and related services to Company.

          E. The Parties entered into an “Endocare Service Agreement” effective February 1, 2004, as
amended by the “Amendment to Endocare Service Agreement” executed December 30, 2004 to be effective
October 1, 2004 (collectively, the “Original Agreement”), pursuant to which Endocare subcontracted
with Company to provide, either directly or through subcontracts with the Business Entities,
certain items and services required to be provided or arranged for by Endocare under the Hospital
Arrangements

          F. The Parties now desire to further amend and restate the Original Agreement, to reflect
additional terms agreed by the Parties, including certain price terms to be effective as of
February 1, 2006.

          NOW, THEREFORE, for and in consideration of the foregoing Recitals, which form a part of this
Agreement, the mutual terms, conditions and covenants contained herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby
agree as follows:

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

 

 

SECTION 1

TERMS OF ENGAGEMENT

          1.1 Hospitals Subject to the Agreement. Company agrees to provide or arrange for the
services described in Section 2 (collectively, the “Services”), in accordance with the
terms and conditions of this Agreement, to hospitals that have entered into Hospital Arrangements
with Endocare (the “Hospitals”). Company acknowledges that this Agreement is not an exclusive
contract, and that Endocare retains the right to engage or permit others to provide one or more of
the Services. **

          1.2 Status of the Parties. Company is an independent contractor of Endocare. Nothing
in this Agreement creates, or shall be construed as creating, an employment relationship between
Company or any of Company’s owners, employees or agents, and Endocare.

          1.3 No Requirement of Referrals by Company Owners. Company shall not condition
eligibility for acquisition or maintenance of an ownership interest in Company, or distributions or
payments from Company, on any consideration of the case volumes or referral patterns of potential
or actual Company owners, including but not limited to performance of cryosurgery at the Hospitals
or usage by any Company owner of Company’s equipment and services. Company also shall not
condition eligibility for or maintenance of a subcontract with any Business Entity, or
distributions or payments from Company to any Business Entity, on any consideration of the case
volumes or referral patterns of Business Entity owners, including but not limited to performance of
cryosurgery at the Hospitals or usage by any Business Entity owner of Company’s or the Business
Entity’s equipment and services.

          1.4 Compliance with Legal Requirements. In connection with this Agreement, each of
the Parties shall comply with, and abide by, and shall cause and require each of its employees and
agents to comply with, and abide by, all federal, state and local laws, rules and regulations now
in force, or which may hereafter be in force, which are applicable to either or both of them or to
the Hospitals. Company represents to Endocare that (1) Company is not excluded from any federal
health care program, as defined under 42 U.S.C. Section 1320a-7b(f), for the provision of items or
services for which payment may be made under a federal health care program; (b) no basis exists for
excluding Company from any health care program; (c) Company has not arranged or contracted (by
employment or otherwise) with any employee, contractor or agent that Company knows or should know
is excluded from participation in any federal health care program; and (d) no final adverse action,
as such term is defined under 42 U.S.C. Section 1320a-7e(g), has occurred or is pending or
threatened against Company, or to its knowledge against any employee, contractor, or agent engaged
by Company to provide items or services under this Agreement (collectively “Exclusions/Adverse
Actions”). Company, during the term of the Agreement, shall notify Endocare of any
Exclusions/Adverse Actions or any basis therefor within fifteen (15) days of its learning of any
such Exclusions/Adverse Actions or any basis therefor.

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-2-

 

          1.5 Subcontracts with Business Entities. Company agrees that each Business Entity
with which Company has or will subcontract for the provision of any of Company’s duties and
responsibilities pursuant to this Agreement has agreed or will agree to comply with all obligations
of Company pursuant to this Agreement, including but not limited to the obligations of Sections
1.3 and 1.4, and any specific Hospital requirements (such as agreement to comply with
any business associate agreement executed by Endocare), before performing any services pursuant to
such subcontract. Endocare’s agreement to permit Company to subcontract for certain services does
not relieve Company of responsibility for the performance of Company’s obligations pursuant to this
Agreement. Company shall provide to Endocare a list of all current Business Entities and any
changes thereto.

          1.6 Compliance Program. Company acknowledges that Company has reviewed Endocare’s
Corporate Compliance Program, as displayed on the following website:
http://www.endocare.com/onendocare/Corp_Compliance_Plan.pdf, which includes Endocare’s Code of
Conduct and Financial Code of Ethics (collectively, the “Program”). Company agrees to comply with
the Program, and to require all Business Entities and Company employees to comply with the Program
in connection with all Company and Business Entity activities relating directly or indirectly to
Company’s obligations under the Agreement. Company acknowledges that the Program includes, among
other requirements, prohibitions on providing or accepting gifts, meals, entertainment or any other
remuneration in return for or to induce the referral, purchasing, prescribing or ordering of any
services that are covered by a federal health care program. Alternatively, Company may establish
to the satisfaction of Endocare that Company and each Business Entity has a suitable fraud and
abuse compliance plan that is substantially equivalent to the Program. If Endocare becomes aware
that Company or any Business Entity is in violation of the Program, the violation will be
considered a material breach of the Agreement and Endocare may terminate the Agreement for cause
under the terms described in Section 5.3.

SECTION 2

DUTIES AND RESPONSIBILITIES OF COMPANY

          2.1 Delivery of Equipment and Supplies; Maintenance and Repairs.

          (a) Company will provide the Equipment to each Hospital during all Scheduled Procedures (as
defined in Section 2.3).

          (b) Company, at its expense, will be responsible for the timely transportation and delivery of
the Equipment to and from each Hospital, and for ensuring that the Equipment is installed and in
working order immediately prior to and during the Scheduled Procedures. Company will store the
equipment, off of the Hospital’s premises, when required to do so by Hospital.

          (c) Company, at its expense, shall keep the Equipment in good repair, condition and working
order, and shall furnish any and all parts, mechanisms and devices required to keep the Equipment
in good mechanical and working order, insofar as the repair,

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-3-

 

parts, mechanisms and devices are not covered under a “warranty”, “service contract” or
“maintenance agreement” during the term of the Agreement. Endocare agrees to respond in timely
maner (within 48 hours) and make any necessary repairs or provide “back-up” equipment if Company’s
equipment is not in good repair, condition and working order

          (d) At Company’s expense, Company will make any alterations, additions, improvements or
modifications to the Equipment as required by law or in order to maintain the Equipment in good
working order, insofar as these alterations, additions, improvements or modifications are not
covered under a “warranty”, “service contract” or “maintenance agreement.” Any necessary software
upgrades will be completed by Endocare at Endocare’s sole expense.

          (e) Upon request, Company shall arrange for the storage and delivery of Disposables (as
defined in Section 3.3).

          2.2 Technician and Technical Support Services. If requested by Endocare, Company
shall provide a technician, who shall be a Company employee or independent contractor, on-site at
the Hospital during all Scheduled Procedures, to provide the services listed in Exhibit B. All
technicians provided by Company shall be trained and certified to maintain and operate the
Equipment pursuant to standards promulgated by Endocare, and shall at all times perform his/her
services in accordance with such standards and any other standards of practice applicable to
his/her services. Company shall ensure that each technician complies with all Hospital policies
and procedures while at the Hospital and meets all Hospital requirements relating to the services
to be rendered.

          2.3 Scheduling. Endocare shall notify, or shall cause the appropriate health care
providers to notify, Company of any request for Company’s Services at a Hospital. Company shall
coordinate with Endocare, the Hospital and the treating physician regarding scheduling the
provision of Company’s Services at the applicable Hospital. Company shall use its best efforts to
schedule such Services at times reasonably acceptable to each Hospital, after taking into account
other requests for Services, and travel and set up time. For purposes of this Agreement, any
scheduling request agreed to by Company shall be a “Scheduled Procedure.” Company shall promptly
notify Endocare of any Scheduled Procedure so that Endocare shall have as much time as possible to
satisfy its obligations under Article 3 below.

SECTION 3

DUTIES AND RESPONSIBILITIES OF ENDOCARE

          3.1 Hospital Arrangements. Endocare will be responsible for entering into Hospital
Arrangements and collecting amounts due from Hospitals

          3.2 Compensation. Endocare shall compensate Company for the Services rendered by
Company in accordance with and subject to the terms and conditions of Section 4.

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-4-

 

          3.3 Probes and Disposables. Endocare shall, at its own cost and expense, provide to
Company or directly to the Hospital all disposable supplies, including CRYOprobesTM, necessary for
each cryoablation procedure (the “Disposables”) at each Hospital for each Scheduled Procedure.
Endocare shall charge the Hospitals fair market value for such Disposables. In cases where Company
(through its technician) will deliver the Disposables, Endocare shall supply Company with an amount
of Disposables necessary to satisfy the projected needs for Scheduled Procedures, and Company shall
store and deliver such Disposables as part of its Services. Company shall execute any agreements
reasonably requested by Endocare to in order to document Endocare’s ownership of the Disposables.

SECTION 4

COMPENSATION

          4.1 Compensation.

          (a) Effective February 1, 2006, Endocare will pay Company a Fee (the “Procedure Fee”) of **
per Scheduled Procedure performed (when Company furnishes both the equipment and the technician) at
a Hospital. If Company provides the Equipment, but does not furnish the technician for a Scheduled
Procedure performed at a Hospital, Endocare will pay Company a Procedure Fee of ** per Schedule
Procedure performed.

          (b) Notwithstanding the provisions of Sections 4.1(a) above, effective February 1,
2006, if a Scheduled Procedure is performed through Company’s subcontract with any of the Business
Entities listed below (the “** Entities”), regardless of the Hospital location, the Procedure Fee
will be ** per Scheduled Procedure performed when Company furnishes both the equipment and the
technician. If Company provides the Equipment, but does not furnish the technician for a Scheduled
Procedure performed through one of the Med Tech Entities, Endocare will pay Company a Procedure Fee
of ** per Schedule Procedure performed. The ** Entities are: **

          (c) **

          (d) The Parties agree that, upon mutual agreement of the Parties, Company may be requested to
provide only certain of the Services in connection with a cryoablation procedure. In such cases,
Endocare’s compensation to Company will be as follows, effective February 1, 2006:

**

          (e) Upon written approval of both parties, Endocare may amend the Procedure Fees on at least
thirty (30) days prior written notice to Company, based on revised compensation under the Hospital
Arrangement(s) and/or to maintain consistency with fair market value.

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-5-

 

          (f) The Parties agree that it is their intent and understanding that the compensation to be
paid by Endocare to Company hereunder shall be consistent with the fair market value for the
services provided; **.

          (g) Both Parties expressly acknowledge that the services to be performed under this Agreement
and the compensation to be paid to Company are not intended, directly or indirectly, to compensate
Company, Company’s owners, any Business Entity or any Business Entity’s owners for referring any
patient to a Hospital or for recommending a Hospital’s or Endocare’s products or services. No
Company or Business Entity owner shall be required to refer any patients to, or order or arrange
for the ordering of any goods, items or services from Hospital or Endocare.

          4.2 Payment Terms.

          (a) Company will submit invoices to Endocare for all Scheduled Procedures performed.
Invoices shall be submitted one (1) time per month. The invoice shall include, for each Scheduled
Procedure: type of case, Hospital, physician and date of service. Company also agrees to submit
copies of encounter forms on a daily basis to Endocare. Company agrees that for all cases known to
Company, encounter forms will be submitted by the last business day of the month by 5:00 p.m.
Pacific Time.

          (b) Endocare will pay Company the Procedure Fee by the ** day following the submission of
invoices inclusive of the information stipulated in Section 4.2(a).**

SECTION 5

TERM AND TERMINATION

          5.1 Term. The initial term of the Original Agreement shall be extended for one year,
through January 31, 2007; thereafter, this Agreement shall be automatically renewed for successive
one (1) year terms, unless terminated earlier as provided in this Section 5.2.

          5.2 Elective Termination. After February 1, 2007, either Party may at any time
terminate this Agreement upon giving the other Party ninety (90) days’ prior written notice.

          5.3 Termination for Cause. Either Party (“terminating party”) shall have the right,
in its sole discretion, to immediately terminate this Agreement by written notice to the other
Party (“non-terminating party”), upon the occurrence of any of the following events:

          (a) The non-terminating party fails to keep, observe or perform any material term or provision
of this Agreement, and such failure is not cured to the reasonable satisfaction of the terminating
party within thirty (30) days after written notice thereof is given by the terminating party to the
non-terminating party setting forth the basis of the purported failure;

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-6-

 

          (b) The non-terminating party ceases doing business as a going concern, is insolvent, makes a
general assignment for the benefit of creditors, admits in writing its inability to pay its debts
as they become due, files a voluntary petition in bankruptcy or for reorganization or any similar
relief under any bankruptcy, insolvency or similar law, has filed against it an involuntary
petition in bankruptcy under any bankruptcy, insolvency or similar law which is not dismissed,
vacated or stayed within sixty (60) days from the date of filing thereof, or has appointed by a
court for it or for any of its property a receiver who is not dismissed within sixty (60) days
after the date of his appointment.

          5.4 Change of Law. If there is a future change in applicable law, including the
interpretation thereof by a court or executive agency, that renders this Agreement or any provision
thereof unlawful or unenforceable, the Parties agree immediately to initiate good faith
negotiations to amend this Agreement to bring it into compliance with applicable law and to
preserve the essential purposes of this Agreement. If either party, acting in good faith,
determines that the Parties will be unable to mutually agree upon and make amendments or
alterations to this Agreement to meet the requirements in question, or alternatively, either party
determines in good faith that amendments or alterations to meet the requirements are not feasible,
then such party may terminate the Agreement on ten (10) days prior written notice to the other
party.

SECTION 6

CONFIDENTIAL INFORMATION

          6.1 Confidential Information. The existing Confidentiality and Non-Disclosure
Agreements signed by the parties on November 14, 2005, is attached as Exhibit A.

SECTION 7

INDEMNIFICATION

          7.1 Indemnification of Endocare. Company shall indemnify and hold Endocare, its
directors, officers, employees, agents, representatives, successors and permitted assigns harmless
from and against (i) any damage or deficiency resulting from any misrepresentation, breach of
warranty or non-fulfillment of any agreement on the part of Company under this Agreement, or from
any misrepresentation or omission from any certificate or other instrument furnished or to be
furnished to Endocare in accordance with the provisions of this Agreement; (ii) any negligent or
willful act or omission by Company, or the employees, directors, officers, independent contractors,
or agents of Company; (iii) any liabilities of or claims against Company or Company’s owners, of
any nature whether accrued, absolute, contingent or otherwise arising out of services performed by
Company hereunder; and (iv) all actions, suits, proceedings, demands, assessments, judgment, costs
and expenses, including reasonable attorney’s fees and expenses, incident to any of the foregoing.

          7.2 Indemnification of Company. Endocare shall indemnify and hold Company, its
directors, officers, employees, agents, representatives, successors and permitted

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-7-

 

assigns harmless from and against (i) any damage or deficiency resulting from any
misrepresentation, breach of warranty or non-fulfillment of any agreement on the part of Endocare
under this Agreement, or from any misrepresentation or omission from any certificate or other
instrument furnished or to be furnished to Company in accordance with the provisions of this
Agreement; (ii) any negligent or willful act or omission by Endocare or its employees, directors,
officers, independent contractors or agents; (iii) any liabilities of or claims against Endocare,
of any nature whether accrued, absolute, contingent or otherwise arising out of services performed
by Endocare hereunder; and (iv) all actions, suits, proceedings, demands, assessments, judgment,
costs and expenses; including reasonable attorney’s fees and expenses, incident to any of the
foregoing.

          7.3 Survival. The terms and conditions of this Section 7 shall survive the
expiration or earlier termination of this Agreement.

SECTION 8

GENERAL PROVISIONS

          8.1 Assignment. Neither Party may assign its rights or delegate its duties under this
Agreement without the prior written consent of the other Party; provided, however, that Company may
delegate certain duties to a Business Entity pursuant to Section 1.5.

          8.2 Entire Agreement; Amendment. This Agreement contains the entire agreement of the
Parties with respect to its subject matter and supersedes all previous and contemporaneous
agreements and understandings, inducements or conditions, expressed or implied, oral or written,
between the Parties with respect to the subject matter hereof, and no waiver, modification or
change of any of its provisions shall be valid unless in writing and signed by the Party against
which such claimed waiver, modification or change is sought to be enforced. Notwithstanding the
foregoing, the Procedure Fees set forth in the Original Agreement shall be effective through
January 31, 2006.

          8.3 Waiver of Breach. The failure of any Party to enforce at any time any of the
provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor
in any way to affect the validity of this Agreement or any part hereof or the right of any Party
thereafter to enforce each and every such provision. The waiver of any breach of any term or
condition of this Agreement is not a waiver of any other term or condition of this Agreement.

          8.4 Force Majeure. Neither Party will be held responsible for failure to perform or
delay in performing its obligations under this Agreement if such failure or delay is caused by a
force majeure such as earthquake, fire, flood, government restrictions, strikes, riots, seizures
and other causes beyond the Parties’ control.

          8.5 Rights of Persons not Parties. Nothing contained in this Agreement shall be
deemed to create rights in persons not Parties, other than successors and proper assigns of the
Parties.

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-8-

 

          8.6 Severability. If any term or provision of this Agreement or application to any
person or circumstance shall to any extent be determined to be invalid or unenforceable, the
remainder of this Agreement or the application of such term or provisions to persons or
circumstances other than those as to which it is held invalid of unenforceable shall not be
affected, and each term and provision of this Agreement shall be valid and enforceable to the
fullest extent permitted by law.

          8.7 Choice of Law. This Agreement shall be governed by and construed and enforced in
accordance with the laws of the state of California.

          8.8 Notices. Any notices required hereunder shall be in writing, shall be delivered
in any one of the following ways, and shall be deemed to have been received (a) on the date
delivered if delivered by hand, (b) the next following business day after being sent if sent by
Federal Express or other similar professional overnight courier, or (c) three (3) business days
after mailing, postage prepaid, by certified mail, return receipt requested, to the Party entitled
to notice at the addresses set forth below, or such other addresses as may be designated by notice
given hereafter:

	 	 	 
	 

	 	Notice to Endocare:
	 

	 	Endocare, Inc.
	 

	 	201 Technology Drive
	 

	 	Irvine, California 92618
	 

	 	Attention: Kevin Quilty, Senior VP, Sales and Marketing
	 
	 	 
	 

	 	Notice to Company:
	 

	 	Advanced Medical Partners, Inc. dba CryoSyndicators
	 

	 	701 Interstate Hwy 20 East
	 

	 	Arlington, TX 76018
	 

	 	Attention: Christopher J. Ringel, President

          8.9 Counterparts. This Agreement may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument. Copies of signatures sent by facsimile transmission shall be deemed to be originals
for purposes of this Agreement.

          IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	 	ENDOCARE, INC.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Michael R. Rodriguez
	 

	 	 	 	 
	 

	 	Name:
	 	Michael R. Rodriguez
	 

	 	 	 	 
	 

	 	Title:
	 	SVP, Finance & CFO
	 

	 	 	 	 
	 

	 	Date:
	 	1/10/06
	 

	 	 	 	 

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-9-

 

	 	 	 	 	 
	 	 	ADVANCED MEDICAL PARTNERS, INC
	 

	 	By:
	 	/s/ Robert A. Yonke
	 

	 	 	 	 
	 

	 	Name:
	 	Robert A. Yonke
	 

	 	 	 	 
	 

	 	Title:
	 	CEO
	 

	 	 	 	 
	 

	 	Date:
	 	01-09-06
	 

	 	 	 	 

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-10-

 

EXHIBIT A

          (“NDA”) Confidentiality Agreements signed by Company and Endocare

**

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-11-

 

EXHIBIT B

JOB DESCRIPTION

CRYO CLINICAL TECHNICIAN

**

** Asterisks indicate confidential terms that were redacted pursuant to a request for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

-12-EXHIBIT 10.1
------------

                                AMENDMENT TO
                            EMPLOYMENT AGREEMENT

      This AMENDMENT TO EMPLOYMENT AGREEMENT dated May 2, 2006 between R.
Craig Yoder (the "Executive") and Landauer, Inc., a Delaware corporation
(the "Company").

      WHEREAS, the Executive and the Company are parties to an Employment
Agreement dated as of February 29, 1996 (the "Employment Agreement"); and

      WHEREAS, the Company and the Executive desire to enter into this
Amendment to Employment Agreement to revise the terms of the Employment
Agreement in certain respects.

      NOW, THEREFORE, in consideration of the premises and the mutual
agreements contained herein, the parties hereby agree as follows:

      1.    Section 1(b) of the Employment Agreement is amended in its
entirety, effective as of April 1, 2006, to read as follows:

            (b)   TERM.  The term of this Agreement (the "Term") shall
commence as of April 1, 2006 (the "Effective Date") and shall continue
until April 1, 2008, and indefinitely thereafter until terminated pursuant
to Section 4 hereof.  As used herein, the term "Employment Period" shall
mean the period commencing on the Effective Date and ending on the date of
termination of the term hereof or Executive's employment with the Company
pursuant to Section 4 hereof.

      2.    A new Section 3(g) is added to the Employment Agreement,
effective as of April 1, 2006, providing as follows:

            (g)   RESTRICTED STOCK.  On the Effective Date, as has been
approved by the Compensation Committee of the Board, the Executive shall be
granted 1,000 shares of restricted Common Stock (the "Restricted Stock").
The shares of Restricted Stock shall become vested on the third anniversary
of the Effective Date.   The Restricted Stock shall be subject to the terms
and provisions of the Company's 2005 Long-Term Incentive Plan.

      3.    Section 4(d) of the Employment Agreement is amended, effective
as of April 1, 2006, to provide that, if the Company terminates the
employment of the Executive for any reason other than a reason set forth in
Section 4(a), 4(b) or 4(c) of the Employment Agreement during the
Employment Period and prior to April 1, 2008, the amount to be paid to the
Executive under Section 4(d)(ii) of the Employment Agreement shall be as
follows:

            (ii)  the Company shall continue to pay the Executive his Base
Salary, Bonus (based on the same percentage of Base Salary as the average
annual Bonuses paid to the Executive for the three fiscal years of the
Company preceding such termination of employment) and all other benefits
which would otherwise be payable hereunder for a period of twenty-four
months following such termination; PROVIDED, HOWEVER, that if, prior to the
end of such twenty-four-month period, the Executive shall obtain employment
with another employer, the amounts otherwise payable pursuant to this
clause (ii) shall be reduced by the amount of compensation earned by the
Executive from his new employment during such period (except that in no
event shall any such reduction result in the Executive receiving an amount
pursuant to this clause (ii) that would be less than the amount the
Executive would have earned if his Base Salary, Bonus and other benefits
had been continued for a period of six months following such termination);

                                      1

<PAGE>

      4.    A new Section 4(g) is added to the Employment Agreement,
effective as of April 1, 2006, providing as follows:

            (g)   DELAY OF PAYMENTS.  In the event that any payment or
distribution to be made to the Executive hereunder is determined to
constitute "deferred compensation" subject to Section 409A of the Code, and
the Executive is determined to be a "specified employee" (as defined in
Section 409A of the Code), such payment or distribution shall not be made
before the date which is six months after the termination of the
Executive's employment (or, if earlier, the date of the Executive's death).

      5.    A new Section 5 is added to the Employment Agreement, and the
subsequent provisions of the Employment Agreement are appropriately
renumbered, effective as of April 1, 2006, providing as follows:

            5.    EXTENSION OF NONCOMPETITION PERIOD.  The Executive agrees
that his noncompetion agreement with the Company will be amended to provide
that, in the event that the Executive's employment is terminated during the
Employment Period and prior to April 1, 2008, the noncompetition period
shall be 24 months.

      6.    The remaining provisions of the Employment Agreement shall not
be changed.

      IN WITNESS WHEREOF, the parties hereto have executed this Amendment
to Employment Agreement as of the day and year first above written.

                                    LANDAUER, INC.

                                    By
                                          ------------------------------

                                    EXECUTIVE:

                                    ------------------------------------
                                    R. Craig Yoder

                                      2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]